חיפוש מתקדם
תחביר
חפש...
הספר "אוצר וולקני"
אודות
תנאי שימוש
ניהול
קהילה:
אסיף מאגר המחקר החקלאי
פותח על ידי קלירמאש פתרונות בע"מ -
Tumor-cell vaccination induces tumor dormancy in a murine model of B-cell leukemia/lymphoma (BCL1)
Year:
1996
Source of publication :
International Journal of Cancer
Authors :
מושל, יאנה
;
.
Volume :
65
Co-Authors:
Morecki, S., Dept. of Bone-Marrow Transplantation, Hadassah University Hospital, Jerusalem 91120, Israel
Pugatsch, T., Dept. of Bone-Marrow Transplantation, Hadassah University Hospital, Jerusalem 91120, Israel
Levi, S., Dept. of Bone-Marrow Transplantation, Hadassah University Hospital, Jerusalem 91120, Israel
Moshel, Y., Dept. of Bone-Marrow Transplantation, Hadassah University Hospital, Jerusalem 91120, Israel
Slavin, S., Dept. of Bone-Marrow Transplantation, Hadassah University Hospital, Jerusalem 91120, Israel
Facilitators :
From page:
204
To page:
208
(
Total pages:
5
)
Abstract:
Immunity to murine B-cell leukemia/lymphoma (BCL1) induced by multiple injections with irradiated tumor cells, prevented leukemia development in primary and adoptive transfer recipients despite long-lasting persistence of residual tumor cells. Detection of dormant BCL1 cells was carried out by PCR analysis using the V(H)-rearranged DNA sequence as a BCL1 clonal marker. Dormant tumor cells were detected >250 days following immunity induction in 40% of spleens from healthy immune mice having no detectable symptoms of disease. Tumor dormancy was not abrogated by adoptive transfer of BCL1-containing splenocytes into syngeneic recipients, indicating that cell-mediated anti-tumor immunity contributes to maintenance of the tumor dormant state and prevents renewed tumor-cell growth. Splenocytes but not sera from immune mice conferred specific radiosensitive protection from a lethal dose of BCL1 cells included in cell mixtures transferred to secondary recipients. A therapeutic effect of transferred immune splenocytes was shown in BCL1-bearing mice, which remained disease-free for >200 days after inoculation; nevertheless, dormant BCL1 cells were detected by PCR analysis in some of the surviving mice. Our results suggest that an efficient tumor-cell vaccine can lead to induction of tumor dormancy that can be maintained by a cell-derived mechanism for a long period of time.
Note:
Related Files :
animal cell
animal experiment
animal model
Animals
cancer vaccine
Lymphoma, B-Cell
mice
Neoplasm, Residual
Vaccination
עוד תגיות
תוכן קשור
More details
DOI :
10.1002/(SICI)1097-0215(19960117)65:2<204::AID-IJC13>3.0.CO;2-D
Article number:
Affiliations:
Database:
סקופוס
Publication Type:
מאמר
;
.
Language:
אנגלית
Editors' remarks:
ID:
22844
Last updated date:
02/03/2022 17:27
Creation date:
16/04/2018 23:54
Scientific Publication
Tumor-cell vaccination induces tumor dormancy in a murine model of B-cell leukemia/lymphoma (BCL1)
65
Morecki, S., Dept. of Bone-Marrow Transplantation, Hadassah University Hospital, Jerusalem 91120, Israel
Pugatsch, T., Dept. of Bone-Marrow Transplantation, Hadassah University Hospital, Jerusalem 91120, Israel
Levi, S., Dept. of Bone-Marrow Transplantation, Hadassah University Hospital, Jerusalem 91120, Israel
Moshel, Y., Dept. of Bone-Marrow Transplantation, Hadassah University Hospital, Jerusalem 91120, Israel
Slavin, S., Dept. of Bone-Marrow Transplantation, Hadassah University Hospital, Jerusalem 91120, Israel
Tumor-cell vaccination induces tumor dormancy in a murine model of B-cell leukemia/lymphoma (BCL1)
Immunity to murine B-cell leukemia/lymphoma (BCL1) induced by multiple injections with irradiated tumor cells, prevented leukemia development in primary and adoptive transfer recipients despite long-lasting persistence of residual tumor cells. Detection of dormant BCL1 cells was carried out by PCR analysis using the V(H)-rearranged DNA sequence as a BCL1 clonal marker. Dormant tumor cells were detected >250 days following immunity induction in 40% of spleens from healthy immune mice having no detectable symptoms of disease. Tumor dormancy was not abrogated by adoptive transfer of BCL1-containing splenocytes into syngeneic recipients, indicating that cell-mediated anti-tumor immunity contributes to maintenance of the tumor dormant state and prevents renewed tumor-cell growth. Splenocytes but not sera from immune mice conferred specific radiosensitive protection from a lethal dose of BCL1 cells included in cell mixtures transferred to secondary recipients. A therapeutic effect of transferred immune splenocytes was shown in BCL1-bearing mice, which remained disease-free for >200 days after inoculation; nevertheless, dormant BCL1 cells were detected by PCR analysis in some of the surviving mice. Our results suggest that an efficient tumor-cell vaccine can lead to induction of tumor dormancy that can be maintained by a cell-derived mechanism for a long period of time.
Scientific Publication
נגישות
menu      
You may also be interested in